Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin Beats Lipitor At LDL-Lowering In Data Analysis

This article was originally published in The Pink Sheet Daily

Executive Summary

A Merck/Schering-Plough-sponsored data analysis presented at the American College of Cardiology Scientific Sessions March 13 showed that more patients treated with Vytorin (ezetimibe/simvastatin) achieved lower levels of LDL cholesterol and apolipoprotein B compared to patients taking Pfizer's Lipitor (atorvastatin)

You may also be interested in...



Vytorin Bolsters LDL-Lowering Claim Over Lipitor With New Study

Ezetimibe/simvastatin advantage over atorvastain is found to be not as great with higher starting doses.

Vytorin Bolsters LDL-Lowering Claim Over Lipitor With New Study

Ezetimibe/simvastatin advantage over atorvastain is found to be not as great with higher starting doses.

Vytorin Data Showing Superiority Over Lipitor Added To Labeling

Merck/Schering-Plough’s labeling update for Vytorin includes results of the VYVA study.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel